ORYX’ therapeutic vaccine MicOryx successfully completes Phase I/IIa trial to treat MSH-H colorectal cancer
4 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or…